Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma - Concepedia

Concepedia

Publication | Open Access

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

DOI Full Paper Access

157

Citations

19

References

2009

Year

Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara J. Gitlitz, Marianna Koczywas, Igor Espinoza‐Delgado, David R. Gandara

Journal of Thoracic Oncology

OncologyHistone Deacetylase InhibitorMedicinePhase Ii StudyPathologyAnti-cancer AgentCancer TreatmentPharmacologyMalignant DiseaseSecond Line TherapyCancer Research

References

	Year	Citations

Page 1

Page 1